CORRECTION: Pomerantz Law Firm Announces the Filing of a Class Action Against Amarin Corporation plc and Certain Officers – AMRN - Yahoo Finance
NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, December 17th by Pomerantz LLP, please note that in the second paragraph, the lead plaintiff deadline has been updated from December 21, 2021 to December 23, 2021. The corrected release follows:
Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-19911, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Amarin securities between December 5, 2018 and June 21, 2021, inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder by the Securities and Exchange Commission.
If you are a shareholder who purchased Amarin securities during the Class Period, you have until December 23, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Amarin is a biopharmaceutical company whose lead product since 2008 is Vascepa® (AMR-101) (“Vascepa”), a prescription grade ultra-pure omega-3 fatty acid derived from fish oil. In July 2012, the U.S. Food and Drug Administration (“FDA”) first approved Vascepa to treat patients with very high levels of triglycerides (“TG”), a type of fat found in blood, and in December 2019, expanded the label to include the reduction of cardiovascular disease events, including heart attack, stroke, and cardiovascular death in high-risk patients.
source: https://finance.yahoo.com/news/correction-pomerantz-law-firm-announces-002900268.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.